Edition:
United Kingdom

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

73.75CHF
22 May 2018
Change (% chg)

CHF0.70 (+0.96%)
Prev Close
CHF73.05
Open
CHF73.20
Day's High
CHF73.95
Day's Low
CHF73.20
Volume
24,109
Avg. Vol
66,044
52-wk High
CHF87.10
52-wk Low
CHF63.75

Latest Key Developments (Source: Significant Developments)

Basilea Pharmaceutica Appoints Gerrit Hauck As CTO
Friday, 27 Apr 2018 

April 27 (Reuters) - BASILEA PHARMACEUTICA AG ::GERRIT HAUCK APPOINTED AS CHIEF TECHNOLOGY OFFICER.  Full Article

Basilea Pharmaceutica FY Operating Loss At CHF 14.1 million
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - BASILEA PHARMACEUTICA AG ::FY ‍54% INCREASE IN TOTAL REVENUE, AMOUNTING TO CHF 101.5 MILLION​.FY OPERATING LOSS REDUCED BY 68% TO CHF 14.1 MILLION.‍CASH POSITION AS OF YEAR-END 2017 INCREASED TO CHF 310.7 MILLION​.‍NET LOSS IN 2017 WAS REDUCED TO CHF 19.4 MILLION (2016: CHF 51.3 MILLION)​.OUTLOOK 2018: ANTICIPATES TOTAL REVENUE OF APPROXIMATELY CHF 105-115 MILLION.OPERATING LOSS IN 2018 IS ESTIMATED AT APPROXIMATELY CHF 10-20 MILLION.  Full Article

Basilea Appoints David Veitch As New CEO
Wednesday, 21 Feb 2018 

Feb 21 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA'S CEO RONALD SCOTT WILL RETIRE. CHIEF COMMERCIAL OFFICER DAVID VEITCH NAMED AS SUCCESSOR. CHANGES IN THE BOARD OF DIRECTORS.DAVID VEITCH TO SUCCEED MR. SCOTT IN ROLE OF CHIEF EXECUTIVE OFFICER EFFECTIVE APRIL 19, 2018.  Full Article

Basilea Announces Completion Of License Agreement Extension With Pfizer
Wednesday, 10 Jan 2018 

Jan 10 (Reuters) - Basilea Pharmaceutica AG ::BASILEA ANNOUNCES COMPLETION OF THE LICENSE AGREEMENT EXTENSION WITH PFIZER FOR ANTIFUNGAL CRESEMBA FOR CHINA AND ASIA PACIFIC.  Full Article

Basilea starts clinical phase 1 study in collaboration with U.S. Adult Brain Tumor Consortium ​
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Basilea Pharmaceutica Ag ::‍INITIATION OF A PHASE 1 STUDY CONDUCTED UNDER ITS CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM IN U.S.​.‍BASILEA EXPECTS TO COMPLETE PHASE 1 PATIENT RECRUITMENT INTO SEPARATE GLIOBLASTOMA ARM OF ORAL STUDY IN FIRST HALF OF 2018​.  Full Article

Basilea: Ceftobiprole Gets QIDP Designation From U.S. FDA
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA REPORTS THAT CEFTOBIPROLE RECEIVED QIDP DESIGNATION FROM U.S. FDA FOR THE TREATMENT OF STAPHYLOCOCCUS AUREUS BACTEREMIA (SAB).  Full Article

Basilea Extends Existing License Agreement With Pfizer For Cresemba
Friday, 1 Dec 2017 

Dec 1 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA EXTENDS EXISTING LICENSE AGREEMENT WITH PFIZER <<>> FOR ANTIFUNGAL CRESEMBA® (ISAVUCONAZOLE) TO CHINA AND ASIA PACIFIC.BASILEA UPDATES ITS FINANCIAL GUIDANCE FOR 2017 - IMPROVED RESULT EXPECTED.ELIGIBLE TO RECEIVE MILESTONE PAYMENTS OF UP TO USD 226 MILLION AND MID-TEEN ROYALTIES ON SALES.WILL RECEIVE UPFRONT PAYMENT OF USD 3 MILLION.FOR FY EXPECTS A REDUCED OPERATING LOSS OF APPROXIMATELY CHF 1 MILLION ON AVERAGE PER MONTH.FOR FY SEES LOWER OPERATING EXPENSES.  Full Article

Basilea Pharmaceutica ‍marketing authorization for Cresemba for Switzerland​
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - BASILEA PHARMACEUTICA AG ::‍MARKETING AUTHORIZATION RECEIVED FOR CRESEMBA FOR SWITZERLAND​.  Full Article

Basilea announces license with Shenzhen China Resources Gosun Pharmaceutical Co
Thursday, 28 Sep 2017 

Sept 28 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA ANNOUNCES LICENSE AGREEMENT FOR ANTIBIOTIC ZEVTERA® (CEFTOBIPROLE) WITH SHENZHEN CHINA RESOURCES GOSUN PHARMACEUTICAL CO., LTD..  Full Article

Basilea says distribution agreement with Cardiome
Tuesday, 12 Sep 2017 

Sept 12 (Reuters) - BASILEA PHARMACEUTICA AG ::BASILEA ANNOUNCES DISTRIBUTION AGREEMENT WITH CARDIOME TO COMMERCIALIZE ANTIBIOTIC ZEVTERA/MABELIO (CEFTOBIPROLE) IN EUROPE AND ISRAEL.‍BASILEA WILL RECEIVE AN UPFRONT PAYMENT OF CHF 5 MILLION​.CARDIOME GRANTED EXCLUSIVE LICENSE TO COMMERCIALIZE CEFTOBIPROLE IN MORE THAN 30 COUNTRIES IN EUROPE AND IN ISRAEL.  Full Article

Swiss stocks - Factors to watch on May 15

ZURICH, May 15 The Swiss blue-chip SMI was seen opening unchanged at 8,998 points on Tuesday, according to premarket indications by bank Julius Baer.